Keywords: gsk, arixtra, cuts, vte, risk, artemis, study

GSK's Arixtra "cuts VTE risk 47%," ARTEMIS study

Article | 20 February 2006

Print This

UK drug major GlaxoSmithKline says that results from the ARTEMIS study of its antithrombotic Arixtra (fondaparinux sodium) show that it ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in